Evaluation of the concentration of marbofloxacin in alveolar macrophages and pulmonary epithelial lining fluid after administration in dogs

American Journal of Veterinary Research

Volumn 66, Issue 10, 2005, Pages 1770-1774

  Boothe, Harry W ^a,c   Jones, Sarah A ^a,d   Wilkie, W Scott ^a,d   Boeckh, Albert ^a,e   Stenstrom, Kristol K ^b,f   Boothe, Dawn M ^a,c  

^a TEXAS A AND M UNIVERSITY   (United States)

^b ZOETIS   (United States)

^c AUBURN UNIVERSITY   (United States)

^d Merial Ltd ^*  (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEPROMAZINE; GLYCOPYRRONIUM BROMIDE; MARBOFLOXACIN; OFLOXACIN; PROPOFOL; VETERINARY DRUG; ZENIQUIN;

ANESTHESIA; ANIMAL CELL; ARTICLE; CELL FRACTIONATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; FEMALE; FIBEROPTIC BRONCHOSCOPY; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFECTION SENSITIVITY; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG INFILTRATE; LUNG LAVAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; SUPERNATANT;

ADMINISTRATION, ORAL; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FLUOROQUINOLONES; MACROPHAGES, ALVEOLAR; QUINOLONES; TIME FACTORS;

ANIMALIA; BACTERIA (MICROORGANISMS); CANIS FAMILIARIS;

EID: 27844468687     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.1770     Document Type: Article

References (30)

1. Loo KC, Cario AC, Zhang F, et al. Regulation of ciprofloxacin uptake in human promyelocytic leukemia cells and polymorphonuclear leukocytes. J Leukoc Biol 1997;61:619-623.
2. Pascual A. Uptake and intracellular activity of antimicrobial agents in phagocytic cells. Rev Med Microbiol 1995;6:228-235.
3. Carlier MB, Scorneaux B, Zenebergh A, et al. Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. J Antimicrob Chemother 1990;26(suppl B):27-39.
4. Easmon CS, Crane JP. Uptake of ciprofloxacin by macrophages. J Clin Pathol 1985;38:442-444.
5. Hawkins EC, Boothe DM, Guinn A, et al. Concentration of enrofloxacin and its active metabolite in alveolar macrophages and pulmonary epithelial lining fluid of dogs. J Vet Pharmacol Ther 1998;21:18-23.
6. Prokesch RC, Hand WL. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1982;21:373-380.
7. Brown SA. Fluoroquinolones in animal health. J Vet Pharmacol Ther 1996;19:1-14.
8. Neer TM. Clinical pharmacologic features of fluoroquinolone antimicrobial drugs. J Am Vet Med Assoc 1988;193:577-580.
9. Spreng M, Deleforge J, Thomas V, et al. Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolates. J Vet Pharmacol Ther 1995; 18:284-289.
10. Schneider M, Thomas V, Boisrame B, et al. Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration. J Vet Pharmacol Ther 1996;19:56-61.
11. Cester CC, Schneider M, Toutain PL. Comparative kinetics of two orally administered fluoroquinolones in dog: enrofloxacin versus marbofloxacin. Revue Méd Vét 1996;147:703-716.
12. Hawkins EC, DeNicola DB, Kuehn NF. Bronchoalveolar lavage in the evaluation of pulmonary disease in the dog and cat. State of the art. J Vet Intern Med 1990;4:267-274.
13. Pascual A, García I, Conejo MC, et al. Fluorometric and high-performance liquid chromatographic measurement of quinolone uptake by human neutrophils. Eur J Clin Microbiol Infect Dis 1991;10:969-971.
14. Hogg JC, McLean T, Martin BA, et al. Erythrocyte transit and neutrophil concentration in the dog lung. J Appl Physiol 1988;65:1217-1225.
15. Crapo JD, Young SL, Fram EK, et al. Morphometric characteristics of cells in the alveolar region of mammalian lungs. Am Rev Respir Dis 1983;128:S42-S46.
16. Marcy TW, Merrill WW, Rankin JA, et al. Limitations of using urea to quantify epithelial lining fluid recovered by bronchoalveolar lavage. Am Rev Respir Dis 1987;135:1276-1280.
17. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986;60:532-538.
18. Gruet P, Richard P, Thomas E, et al. Prevention of surgical infections in dogs with a single intravenous injection of marbofloxacin: an experimental model. Vet Rec 1997;140:199-202.
19. Schüler P, Zemper K, Borner K, et al. Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. Eur Respir J 1997;10:1130-1136.
20. Tulkens PM. Accumulation and subcellular distribution of antibiotics in macrophages in relation to activity against intracellular bacteria. In: Fass RG, ed. Ciprofloxacin in pulmonology. San Francisco: W Zuckschwerdt Vering Munchen, 1990;12-20.
21. Wise R, Baldwin DR, Andrews JM, et al. Comparative pharmacokinetic disposition of fluoroquinolones in the lung. J Antimicrob Chemother 1991;28(suppl C):65-71.
22. Dargaville PA, South M, Vervaart P, et al. Validity of markers of dilution in small volume lung lavage. Am J Respir Crit Care Med 1999;160:778-784.
23. Jacks S, Giguère S, Gronwall PR, et al. Pharmacokinetics of azithromycin and concentration in body fluids and bronchoalveolar cells in foals. Am J Vet Res 2001;62:1870-1875.
24. Davis JL, Gardner SY, Jones SL, et al. Pharmacokinetics of azithromycin in foals after i.v. and oral dose and disposition into phagocytes. J Vet Pharmacol Ther 2002;25:99-104.
25. Greene CE. Respiratory infections. In: Greene CE, ed. Infectious diseases of the dog and cat. 2nd ed. Philadelphia: WB Saunders Co, 1998;582-594.
26. Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: in vitro and animal models. Ann Pharmacother 2003;37:1287-1298.
27. Scheld WM. Maintaining fluroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003;9:1-9.
28. Doern GV, Tillotson GS. What have we learned about antimicrobial prescribing? Antimicrob Infect Dis News 2002;18:81-86.
29. Paladino JA, Callen WA. Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodymic parameters. J Antimicrob Chemother 2003;51(suppl 1):43-47.
30. Toutain PL, del Castillo JR, Bousquet-Melou A. The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Res Vet Sci 2002;73:105-114.